Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Frasers walks away from Revolution Beauty sale process

(Sharecast News) - Retail conglomerate Frasers Group has walked away from the Revolution Beauty bidding process, just 10 days after confirming its interest. In a statement to the market on Thursday, the Sports Direct and Evans Cycles owner confirmed that it "does not intend to make an offer" for the cosmetics and make-up ecommerce brand.

On 9 June, Frasers had confirmed its participation in due diligence as part of the sale process which kicked off in mid-May, as Revolution said it was reviewing funding options before a credit facility expires later this year. At the time, Frasers said that any potential offer would be for the full issued share capital and be all cash.

Now, Frasers' exit from the formal sale process means, under UK Takeover Panel rules, that it cannot return to the negotiating table for six months, unless it has full agreement from Revolution's board or there is a material change in circumstances.

Last Thursday, Revolution Beauty said it had received proposals from "a number of parties" and was evaluating the bids with its financial adviser, giving further access to diligence materials in some cases.

Revolution said it was also continuing "positive engagement" with its shareholders, including in respect of an equity raise, and is making progress on its cost structure and go-to-market strategy.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.